Abstract
Editor's note: After a distinguished career in academic medicine, including stints at the Children's Hospital of Philadelphia, INSERM and Genethon, Federico Mingozzi joined Spark Therapeutics 3 years ago as chief scientific officer. Mingozzi aims to build on the company's landmark success with Luxturna, the approved therapy for certain retinal diseases such as the type 2 version of Leber's congenital amaurosis. In this exclusive interview with Human Gene Therapy Executive Editor Kevin Davies, Mingozzi discusses his career highlights and surveys the hopes and challenges facing the human gene therapy community.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
